Open Access

Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA

  • Authors:
    • Yan Sun
    • Rui Meng
    • Heng Tang
    • Huimin Wang
    • Xueqin Guo
    • Yuanyuan Ma
    • Yun Yang
    • Xiaoming Wei
    • Feng Mu
    • Gang Wu
    • Jun Wang
    • Jun Liu
    • Mingshan Niu
    • Jun Xue
  • View Affiliations

  • Published online on: April 12, 2019     https://doi.org/10.3892/ol.2019.10243
  • Pages: 5369-5376
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Circulating tumor DNA (ctDNA) has been frequently investigated to monitor tumor dynamics and measure tumor burden. This non‑invasive method concerning ctDNA has been recognized as a promising biomarker. Recently, next generation sequencing has been used in ctDNA detection by researchers. However, those reports have been limited by modest sensitivity, and only a minority of patients with cancer were applicable. Additionally, a limited number of cases of liver cancer have been analyzed. A more precise method is required to be established to evaluate ctDNA noninvasively. In the present study, a novel method to design a liver cancer‑associated chip region (spanning 211 kb, containing 159 genes) was performed with high specificity using International Cancer Genome Consortium datasets. Following evaluation with datasets from The Cancer Genome Atlas and data from 3 patients with liver cancer, the selected regions were demonstrated to be beneficial to locate specific somatic mutations associated with liver cancer therapy and to monitor cancer dynamics in the plasma samples of the patients. In addition to establishing performance benchmarks supporting direct clinical use, the chip designed and the high‑resolution sequencing analyses pipeline would allow the development a set of patient specific markers that could monitor the process of cancer with high accuracy and low cost. Furthermore, the present study is essential to understanding the dynamics and providing insight into the basic mechanisms of liver cancer.

References

1 

Ignatiadis M and Dawson SJ: Circulating tumor cells and circulating tumor DNA for precision medicine: Dream or reality? Ann Oncol. 25:2304–2313. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, et al: Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2:20ra142010. View Article : Google Scholar : PubMed/NCBI

3 

van der Vaart M, Semenov DV, Kuligina EV, Richter VA and Pretorius PJ: Characterisation of circulating DNA by parallel tagged sequencing on the 454 platform. Clin Chim Acta. 409:21–27. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, et al: Cancer genome scanning in plasma: Detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 59:211–224. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Chen JG and Zhang SW: Liver cancer epidemic in China: Past, present and future. Semin Cancer Biol. 21:59–69. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Mabert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S and Dubrovska A: Cancer biomarker discovery: Current status and future perspectives. Int J Radiat Biol. 90:659–677. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Pantel K and Alix-Panabieres C: Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Res. 73:6384–6388. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al: An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 20:548–554. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, et al: COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38 (Database Issue). D652–D657. 2010. View Article : Google Scholar

11 

Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 134:3792008. View Article : Google Scholar

12 

Kumar B, Singh S, Skvortsova I and Kumar V: Promising targets in anti-cancer drug development: Recent updates. Curr Med Chem. 24:4729–4752. 2017.PubMed/NCBI

13 

Jahangiri P, Pournazari K, Torigian DA, Werner TJ, Swisher-McClure S, Simone CB II and Alavi A: A prospective study of the feasibility of FDG-PET/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy. Eur J Nucl Med Mol Imaging. 46:206–216. 2019. View Article : Google Scholar : PubMed/NCBI

14 

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, et al: Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 4:136ra1682012. View Article : Google Scholar

15 

Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, et al: Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 6:87602015. View Article : Google Scholar : PubMed/NCBI

16 

Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS and Poultsides GA: Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 6:2549–2561. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sun, Y., Meng, R., Tang, H., Wang, H., Guo, X., Ma, Y. ... Xue, J. (2019). Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA. Oncology Letters, 17, 5369-5376. https://doi.org/10.3892/ol.2019.10243
MLA
Sun, Y., Meng, R., Tang, H., Wang, H., Guo, X., Ma, Y., Yang, Y., Wei, X., Mu, F., Wu, G., Wang, J., Liu, J., Niu, M., Xue, J."Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA". Oncology Letters 17.6 (2019): 5369-5376.
Chicago
Sun, Y., Meng, R., Tang, H., Wang, H., Guo, X., Ma, Y., Yang, Y., Wei, X., Mu, F., Wu, G., Wang, J., Liu, J., Niu, M., Xue, J."Design of a liver cancer‑specific selector for the analysis of circulating tumor DNA". Oncology Letters 17, no. 6 (2019): 5369-5376. https://doi.org/10.3892/ol.2019.10243